ReviewDrugs2013
Therapeutic options for visceral leishmaniasis.
Review in Drugs, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 92 citations in OpenAlex.
- Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.Veterinary research communications · 2018Trial
- Dicentrine, an Aporphine Alkaloid From Ocotea langsdorffii, Induces Mitochondrial Dysfunction and Oxidative Stress in Leishmania (L.) infantum.Chemistry & biodiversity · 2026Article
- Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis.The Journal of antimicrobial chemotherapy · 2026Article
- In vitro drug susceptibility of Leishmania donovani from visceral leishmaniasis patients with and without HIV coinfection in Northwestern Ethiopia.Scientific reports · 2025Article
- Spatial analytics to elucidate the incubation period and drivers of visceral leishmaniasis: case of Turkana County in Kenya.Frontiers in digital health · 2025Article
- Can letrozole be repurposed for the treatment of visceral leishmaniasis?Antimicrobial agents and chemotherapy · 2024Article
- Nicotinamide mitigates visceral leishmaniasis by regulating inflammatory response and enhancing lipid metabolism.Parasites & vectors · 2024Article
- A novel outlook in the delivery of artemisinin: production and efficacy in experimental visceral leishmaniasis.Pathogens and global health · 2024Article
- Isolation of potent antileishmanial agents fromJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023Article
- Immunosuppressants alter the immune response associated with GlucantimeFrontiers in immunology · 2023Article
- A Ferrier glycosylation/RSC advances · 2022Article
- Evaluation of In vitro and In vivo Protective Efficacy of Bauhinia variegata Against Leishmania donovani in Murine Model.Acta parasitologica · 2021Article
- Collaborative virtual screening to elaborate an imidazo[1,2-RSC medicinal chemistry · 2021Article
- Integrative genomic, proteomic and phenotypic studies of Leishmania donovani strains revealed genetic features associated with virulence and antimony-resistance.Parasites & vectors · 2020Article
- Recuperating Biopharmaceutical Aspects of Amphotericin B and Paromomycin Using a Chitosan Functionalized Nanocarrier via Oral Route for Enhanced Anti-leishmanial Activity.Frontiers in cellular and infection microbiology · 2020Article
- Antileishmanial activity of terpenylquinones on Leishmania infantum and their effects on Leishmania topoisomerase IB.International journal for parasitology. Drugs and drug resistance · 2019Article
- Therapeutic Interventions for Countering Leishmaniasis and Chagas's Disease: From Traditional Sources to Nanotechnological Systems.Pathogens (Basel, Switzerland) · 2019Review
- Resistance of Leishmania infantum to allopurinol is associated with chromosome and gene copy number variations including decrease in the S-adenosylmethionine synthetase (METK) gene copy number.International journal for parasitology. Drugs and drug resistance · 2018Article
- Monocyte subpopulations as important biomarkers of resistence and susceptibility during experimental infection with Leishmania (Leishmania) major.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2018Article
- Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.Clinical microbiology reviews · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Visceral leishmaniasis (VL), also known as Kala-Azar, is a disseminated protozoal infection caused principally by Leishmania donovani and Leishmania infantum (known as Leishmania chagasi in South America). The therapeutic options for VL are diverse and depend on different factors, such as the geographical area of the infection, development of resistance to habitual treatments, HIV co-infection, malnourishment and other concomitant infections. This article provides an exhaustive review of the literature regarding studies published on the treatment of VL, and gives therapeutic recommendations stratified according to their level of evidence, the species of Leishmania implicated and the geographical location of the infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.